Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00945490 · ClinicalTrials.gov registry record · Phase 3
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
A Phase 3 study, sponsored by Nymox Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT00945490: Completed Phase 3 study, sponsored by Nymox Corporation.
NCT00945490 is a Phase 3 study that has completed, run by Nymox Corporation. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00945490, a Phase 3 study, has completed, sponsored by Nymox Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.
Interventions
- DRUG Placebo
- DRUG NX-1207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2009-05 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00945490
The ClinicalTrials.gov registry entry for NCT00945490 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nymox Corporation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00945490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00945490 about?
NCT00945490 is a clinical study titled "Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018". This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.
What is the current status of trial NCT00945490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2009-05. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00945490?
The interventions under investigation include: Placebo (DRUG), NX-1207 (DRUG).
Who is sponsoring clinical trial NCT00945490?
This trial is sponsored by Nymox Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.